Market closedNon-fractional
SpringWorks/SWTX
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX
About SpringWorks
SpringWorks Therapeutics Inc is a clinical stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers.
Ticker
SWTX
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Stamford, United States
Employees
305
Website
www.springworkstx.com
SpringWorks Metrics
BasicAdvanced
$2.8B
Market cap
-
P/E ratio
-$5.14
EPS
0.83
Beta
-
Dividend rate
Price and volume
Market cap
$2.8B
Beta
0.83
Financial strength
Current ratio
6.846
Quick ratio
6.56
Long term debt to equity
0.984
Total debt to equity
1.156
Management effectiveness
Return on assets (TTM)
-36.63%
Return on equity (TTM)
-63.12%
Valuation
Price to revenue (TTM)
92.97
Price to book
4.86
Price to tangible book (TTM)
4.86
Price to free cash flow (TTM)
-10.04
Growth
Earnings per share change (TTM)
0.69%
3-year revenue growth
-8.91%
3-year earnings per share growth
56.62%
What the Analysts think about SpringWorks
Analyst Ratings
Majority rating from 8 analysts.
SpringWorks Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$21M
288.89%
Net income
-$87M
-7.42%
Profit margin
-415.71%
-76.19%
SpringWorks Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$1.25
-$1.27
-$1.45
-$1.18
-
Expected
-$1.26
-$1.33
-$1.24
-$1.17
-$1.12
Surprise
-0.95%
-4.51%
16.89%
0.71%
-
SpringWorks News
AllArticlesVideos
Kuehn Law Encourages Investors of SpringWorks, Therapeutics Inc. to Contact Law Firm
PRNewsWire·2 days ago
SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
GlobeNewsWire·3 days ago
SpringWorks Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for SpringWorks stock?
SpringWorks (SWTX) has a market cap of $2.8B as of July 04, 2024.
What is the P/E ratio for SpringWorks stock?
The price to earnings (P/E) ratio for SpringWorks (SWTX) stock is 0 as of July 04, 2024.
Does SpringWorks stock pay dividends?
No, SpringWorks (SWTX) stock does not pay dividends to its shareholders as of July 04, 2024.
When is the next SpringWorks dividend payment date?
SpringWorks (SWTX) stock does not pay dividends to its shareholders.
What is the beta indicator for SpringWorks?
SpringWorks (SWTX) has a beta rating of 0.83. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell SpringWorks stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.